

## NOTICE

### ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

99114013	<i>Tocilizumab</i>		1	162mg/0.9 ml (4 ml)	S.C. Inj. Sol.		
99114014	<i>Tocilizumab</i>		1	162 mg/0.9 ml (10 ml)	S.C. Inj. Sol.		
99114015	<i>Tocilizumab</i>		1	162 mg/0.9 ml (20 ml)	S.C. Inj. Sol.		

until the following medication, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, is no longer out of stock:

02424770	<i>Actemra</i>	Roche	4	162 mg/0.9 ml	S.C. Inj. Sol (syr)	1420.00	355.0000
02483327	<i>Actemra</i>	Roche	4	162 mg/0.9 ml	S.C. Inj. Sol (pen)	1420.00	355.0000

This notice has effect retroactively from 11 July 2022.

Québec, 22 July 2022

*[original signed by]*

MARCO THIBAUT  
President and Chief Executive Officer  
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.